Skip to content

Penumbra PEN Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%

Valuation

See full
Market cap$12.48B+25.1%
Enterprise value$12.45B+26.8%
P/E72.9×-163×
P/S8.6×+0.5×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Penumbra’s reported figures.

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Penumbra's free cash flow?
Penumbra (PEN) reported free cash flow of $73.3M in Q1 2026.
How has Penumbra's free cash flow changed year-over-year?
Penumbra's free cash flow increased by 106.5% year-over-year, from $35.5M to $73.3M.
What is the long-term trend for Penumbra's free cash flow?
Over 4 years (2021 to 2025), Penumbra's free cash flow has grown at a 96.7% compound annual growth rate (CAGR), from -$11.68M to $174.93M.